Global Scleroderma diagnostics and therapeutics market is anticipated to witness growth during the forecast period. Increasing prevalence of scleroderma and rising incidences of genetic mutations coupled with drastic changes in environment is the high impact rendering drivers. According to International reports from Japan and Britain, prevalence of systemic scleroderma is around 35 cases per 1 million adults. Women are four times more prone to develop systemic scleroderma than men. In addition, presence of high unmet medical needs and the subsequent introduction of new products catering to these needs are expected to serve this market as future growth opportunities.
Diffuse scleroderma and limited scleroderma are types of scleroderma. Laboratory tests are used for the detection of antibodies associated with scleroderma such as antitopoisomerase antibodies (anti-scl70), anti-U3, and anticentromere antibodies. A complete metabolic panel, complete blood count, thyroid function test, muscle enzymes, and urinalysis are indicated for patients with scleroderma. Calcium channel blockers, alpha blockers, local nitrates, statins, serotonin receptor antagonists, angiotensin II receptor inhibitors, and other drugs such as azathioprine, tetracycline antibiotics, prostanoids, cyclophosphamide, and prokinetics are used for the treatment of scleroderma.
Geographically, the scleroderma diagnostics and therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the most matured region in this market. The presence of favorable government regulations and funding programs coupled with high market penetration rates coupled is the major driver for regional market growth. Moreover, the presence of an extensive number of clinical trials aimed at enhancing efficacy and new product development in the region is expected to fuel future market growth. Asia Pacific emerged as the fastest-growing region owing to a large presence of unmet patient needs and the consequent rise in usage rates. Furthermore, the presence of favorable government initiatives in Japan and Australia is expected to drive market growth during the forecast period.
Key market players for scleroderma diagnostics and therapeutics market include Active Biotech AB, Angion Biomedica Corp., Allergan, Inc., BioLineRx, Ltd., Bayer AG, Bristol-Myers Squibb Company, Corbus pharmaceuticals, Inc., Digna Biotech, S.L., Daval International Ltd., F. Hoffmann-La Roche Ltd., Dynavax Technologies Corporation, GlaxoSmithKline plc, Fibrocell Science, Inc., MedImmune, LLC, iBio, Inc., Vida Therapeutics Inc., NovaLead Pharma Pvt. Ltd. and VivaCell Biotechnology Espana S.L.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.